ClinicalTrials.gg
Active, not recruitingNCT06407934ESTUARYUpdated Jul 10, 2026

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

A Phase 3 interventional study of Amlitelimab and Placebo in Dermatitis Atopic, sponsored by Sanofi. Active, not recruiting at 324 sites in 27 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,541
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing amlitelimab in Dermatitis, Atopic — none open to participants now, 4 under way, 3 of them phase 3. amlitelimab · Dermatitis, Atopic.

Enrollment
2nd of 11
1,541 · median 589
Started
2024
with 3 others
Phase 3
5 of 11
none open now
Registered
10th of 11
by date
Lead sponsor
9 of 11
Sanofi

Among the 11 studies testing amlitelimab in Dermatitis, Atopic, this one is the 2nd largest by enrollment, is one of 4 that started in 2024, is one of 5 in phase 3, and was the 10th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 11 studies testing amlitelimab in Dermatitis, Atopic is open now. The open studies under Dermatitis, Atopic, anywhere →

About amlitelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing amlitelimab in Dermatitis, Atopic as a file.
02

Study summary

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD).

The primary objective of ESTUARY is to assess the maintenance of treatment response on continued Q12W dosing compared to treatment withdrawal.

Study details include:

The study duration will be up to 68 weeks including a 52-week randomized double-blind period, and a 16-week safety follow-up for participants not entering the LTS17367 (RIVER-AD).

The study duration will be up to 52 weeks for participants entering the LTS17367 [RIVER-AD] study at the Week 52 visit of EFC17600 (ESTUARY).

03

Conditions studied

  • Dermatitis Atopic

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be at least 12 years of age inclusive, at the time the is signed.
  • Must have participated, received study treatment without permanent medicinal product (IMP) discontinuation, and adequately completed the assessments required for the treatment period in one of the three 24-week parent studies EFC17559 (COAST-1), EFC17560 (COAST-2) or EFC17561 (SHORE) for moderate-to-severe AD.
  • Able and willing to comply with requested study visit and procedures.
  • Body weight must be ≥ 25 kg.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Developed a medical condition that would preclude participation as described in Exclusion Criteria or Permanent Discontinuation of EFC17559 (COAST-1)/EFC17560 (COAST-2)/EFC17561 (SHORE) clinical trial protocols.
  • Having received any prohibited medication or procedure for AD that resulted in IMP discontinuation in the parent study EFC17559 (COAST-1), EFC17560 (COAST-2) or EFC17561 (SHORE).
  • Participants who, during their participation in the parent study EFC17559 (COAST-1) /EFC17560 (COAST-2)/EFC17561 (SHORE), developed an adverse event (AE) or a serious adverse event (SAE) deemed related to amlitelimab, which in the opinion of the Investigator could indicate that continued treatment with amlitelimab may present an unreasonable risk for the participant.
  • Participants who have had IMP permanently discontinued for any reason before or at the time of the planned first dose in the EFC17600 (ESTUARY) study.
  • Conditions in the parent study EFC17559 (COAST-1)/EFC17560 (COAST-2)/EFC17561 (SHORE) that led to Investigator - or Sponsor-initiated withdrawal of participant from the study (eg, non-compliance, inability to complete study assessments, etc.).
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,541 participants (actual)

Study arms

  • Experimental
    Amlitelimab dose 1

    Subcutaneous injection as per protocol

    Drug: Amlitelimab

  • Experimental
    Amlitelimab dose 2

    Subcutaneous injection as per protocol

    Drug: Amlitelimab

  • Placebo comparator
    Placebo

    Subcutaneous injection as per protocol

    Drug: Placebo

Interventions

  • Pharmaceutical form: Injection solution Route of administration: Subcutaneous (SC) injection

    Also known as: SAR445229

  • DrugPlacebo

    Pharmaceutical form: Injection solution Route of administration: SC injection

06

What researchers measure

Primary outcomes

  1. US and US reference countries: Proportion of participants who are responders AND maintained vIGA-AD ≤2 without experiencing relapse among participants who were responders at baseline of ESTUARY

    Clinical response is defined as having vIGA-AD 0 or 1. Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^. The validated Investigator Global Assessment scale for atopic dermatitis (vIGA-AD) is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The Eczema Area and Severity Index (EASI) is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Week 24

  2. EU, EU Reference Countries, and Japan: Proportion of participants who maintain treatment response in ESTUARY without experiencing relapse

    Maintenance of clinical response is defined as having vIGA-AD 0 or 1 OR EASI-75\^ OR vIGA-AD 0 or 1 and EASI-75\^. Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Week 48

Secondary outcomes

  1. Proportion of participants who continue to be EASI-75^ among the participants who met EASI-75^ at baseline of ESTUARY

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  2. Proportion of participants who continue to be vIGA-AD 0 or 1 among participants who met vIGA-AD 0 or 1 at baseline of ESTUARY

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Up to Week 48

  3. Proportion of participants who continue to be vIGA-AD 0 or 1 with presence of only barely perceptible erythema among the participants who were vIGA-AD 0 or 1 with presence of only barely perceptible erythema at baseline of ESTUARY

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). Only barely perceptible erythema = no induration/papulation, no lichenification, no oozing or crusting.

    Time frame: Up to Week 48

  4. Proportion of participants who maintained weekly average of daily PP-NRS reduction of ≥4^ among the participants with weekly average of daily PP-NRS reduction of ≥ 4^ at baseline of ESTUARY

    The Peak Pruritus-Numerical Rating Scale (PP-NRS) is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  5. Proportion of participants who maintain treatment response without experiencing relapse

    Maintenance of treatment response is defined as having vIGA-AD 0 or 1 OR EASI-75\^ OR vIGA-AD 0 or 1 and EASI-75\^. Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: Up to Week 48

  6. Percent change in EASI from parent study baseline

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: Parent study baseline to Week 48

  7. Proportion of participants who maintained EASI-75^ without experiencing relapse among the participants who met EASI-75^ at baseline of ESTUARY

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  8. Proportion of participants with EASI-75^

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  9. Proportion of participants who continue to be EASI-90^ among the participants who met EASI-90^ at baseline of ESTUARY

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-90 is 90% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  10. Proportion of participants with EASI-90^

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-90 is 90% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  11. Time to the first event of vIGA-AD ≥3 or loss of EASI-75^ among the participants who were vIGA-AD 0 or EASI-75^ at baseline of ESTUARY

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  12. Proportion of participants with vIGA-AD 0 or 1

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Up to Week 48

  13. Proportion of participants who are vIGA-AD 0 or 1 with presence of only barely perceptible erythema (no induration/papulation, no lichenification, no oozing or crusting)

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Up to Week 48

  14. EU, EU Reference Countries, and Japan: Time to first event of vIGA-AD ≥3 or loss of EASI^75 among those participants who were vIGA-AD 0 or 1 at baseline of ESTUARY

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  15. EU, EU Reference Countries, and Japan: Time to first event of vIGA-AD ≥3 or loss of EASI^75 among those participants who were vIGA-AD 0 at baseline of ESTUARY

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  16. Proportion of participants with weekly average of daily PP-NRS reduction of ≥4^

    The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable. The symbol \^ represents "based on parent study baseline".

    Time frame: Parent study baseline to Week 48

  17. Proportion of participants who maintain PP-NRS ≤4 among participants who were PP-NRS ≤4 at baseline of ESTUARY

    The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Up to Week 48

  18. EU, EU Reference Countries, and Japan: Proportion of participants who maintain reduction in POEM ≥4^ among the participants with reduction in POEM ≥4^ at baseline of ESTUARY

    The Patient Oriented Eczema Measure (POEM) is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  19. EU, EU Reference Countries, and Japan: Proportion of participants with a reduction in CDLQI ≥6^ among participants aged ≥12 to <16 years old and with reduction in CDLQI ≥6^ at baseline of ESTUARY

    The Children's Dermatology Quality of Life Index (CDLQI) is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-\<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  20. EU, EU Reference Countries, and Japan: Proportion of participants with ≥ 4 reduction in DLQI ≥4^ among the participants aged ≥16 years old and with reduction in DLQI ≥4^ at baseline of ESTUARY

    The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.

    Time frame: Up to Week 48

  21. Percentage of participants who experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and/or Treatment-Emergent Adverse Events of Special Interest (AESI)

    Time frame: Up to week 68

  22. Pharmacokinetic: Serum amlitelimab concentrations

    Time frame: Up to Week 68

  23. Incidence of antidrug antibodies (ADAs) of amlitelimab

    Time frame: Up to Week 68

  24. Pharmacokinetic: maximum plasma concentration (Cmax)

    Time frame: Up to Week 68

  25. Pharmacokinetic: AUC4W and AUC12W

    Cumulative area under the serum concentration curve over 4 weeks (AUC4W). Cumulative area under the serum concentration curve over 12 weeks (AUC12W).

    Time frame: Up to Week 4 and 12

  26. Proportion of participants who are EASI-75^ among participants who had EASI-75^ at baseline of ESTUARY and did not relapse by Week 12

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  27. Time to first recapture of EASI-75^ among participants who had EASI-75^ at baseline of ESTUARY and subsequently relapsed

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  28. Proportion of participants who recapture EASI-75^ by visit among the participants who had EASI-75^ at baseline of ESTUARY and subsequently relapsed

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  29. Proportion of participants who are EASI 90^ AND who maintain EASI-75^ without experiencing relapse among participants who had EASI-90^ at baseline of ESTUARY

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  30. Proportion of participants who are EASI 90^ without experiencing relapse among participants who had EASI-90^ at baseline of ESTUARY

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  31. Proportion of participants who are EASI-90^ among participants who had EASI-90^ at baseline of ESTUARY and did not relapse by Week 12.

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  32. Proportion of participants who are vIGA-AD 0 or 1 AND who maintain vIGA-AD ≤2 without experiencing relapse among participants who had vIGA-AD 0 or 1 at baseline of ESTUARY

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  33. Proportion of participants who maintain vIGA-AD response within 1 point of baseline without experiencing relapse among participants who had vIGA-AD 0 or 1 at baseline of ESTUARY

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  34. Proportion of participants who maintain vIGA-AD 0 or 1 without experiencing relapse among participants who had vIGA-AD 0 or 1 at baseline of ESTUARY

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  35. Proportion of participants who are vIGA-AD 0 or 1 without experiencing relapse among participants who had vIGA-AD 0 or 1 at baseline of ESTUARY

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  36. Time to first recapture of vIGA-AD 0 or 1 among participants who had vIGA-AD 0 or 1 at baseline of ESTUARY and subsequently relapsed

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Up to Week 48

  37. Proportion of participants who recapture vIGA-AD 0 or 1 among participants who had vIGA-AD 0 or 1 at baseline of ESTUARY and subsequently relapsed

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Up to Week 48

  38. Proportion of participants who are vIGA-AD 0 or 1 among participants who had vIGA-AD 0 or 1 at baseline of ESTUARY and did not relapse by Week 12

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  39. Proportion of participants who are vIGA-AD 0 or 1 with only barely perceptible erythema AND who maintain vIGA-AD ≤2 without experiencing relapse among participants who had vIGA-AD 0 or 1 with only barely perceptible erythema at baseline of ESTUARY

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline". Only barely perceptible erythema = no induration/papulation, no lichenification, no oozing or crusting.

    Time frame: Up to Week 48

  40. Proportion of participants who are vIGA-AD 0 or 1 with presence of only barely perceptible erythema among participants who had vIGA-AD 0 or 1 with presence of only barely perceptible erythema at baseline of ESTUARY and did not relapse by Week 12

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline". Only barely perceptible erythema = no induration/papulation, no lichenification, no oozing or crusting.

    Time frame: Up to Week 48

  41. Proportion of participants who maintain weekly average of daily PP-NRS reduction of ≥4^ without experiencing relapse among participants with weekly average of daily PP NRS reduction of ≥4^ at baseline of ESTUARY

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  42. Proportion of participants who maintain PP NRS ≤4 without experiencing relapse among participants who had PP-NRS ≤4 at baseline of ESTUARY

    Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  43. Proportion of participants who achieve PP-NRS reduction of ≥4

    The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Up to Week 48

  44. Proportion of participants who achieve PP-NRS ≤4

    The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.

    Time frame: Up to Week 48

  45. Duration of maintained response without relapse

    Maintenance of clinical response is defined as having vIGA-AD 0 or 1 OR EASI-75\^ OR vIGA-AD 0 or 1 and EASI-75\^. Relapse is defined as having vIGA-AD ≥3 or loss of EASI-75\^ The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75\^ is 75% reduction from baseline in EASI score. The symbol \^ represents "based on parent study baseline".

    Time frame: Up to Week 48

  46. Percent change in Head & Neck EASI sub-score from the parent study baseline among participants with Head & Neck EASI sub-score >0 at baseline of the parent study

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Four body areas are considered separately: Head \& Neck, Trunk including genital area, Upper extremities and Lower extremities including the buttocks. Head \& Neck sub-score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.

    Time frame: From parent study baseline to Week 48

  47. Proportion of participants Head & Neck EASI sub-score EASI-75^ among participants with Head & Neck EASI sub-score >0 at baseline of the parent study

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Four body areas are considered separately: Head \& Neck, Trunk including genital area, Upper extremities and Lower extremities including the buttocks. Head \& Neck sub-score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. Head \& Neck EASI sub-score EASI-75 is 75% reduction from baseline in Head \& Neck EASI sub-score. The symbol \^ represents "based on parent study baseline"

    Time frame: From parent study baseline to Week 48

  48. Proportion of participants with Head & Neck EASI sub-score EASI-90^ among participants with Head & Neck EASI sub-score >0 at baseline of parent study

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Four body areas are considered separately: Head \& Neck, Trunk including genital area, Upper extremities and Lower extremities including the buttocks. Head \& Neck sub-score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. Head \& Neck EASI sub-score EASI-90 is 90% reduction from baseline in Head \& Neck EASI sub-score. The symbol \^ represents "based on parent study baseline"

    Time frame: From parent study baseline to Week 48

07

Study locations

324 sites
  • Cahaba Dermatology & Skin Health Center- Site Number : 8401066
    Birmingham, Alabama 35244, United States
  • Center for Dermatology and Plastic Surgery- Site Number : 8401119
    Scottsdale, Arizona 85260, United States
  • Scottsdale Clinical Trials- Site Number : 8401149
    Scottsdale, Arizona 85260, United States
  • Eclipse Clinical Research- Site Number : 8401158
    Tucson, Arizona 85745, United States
  • Johnson Dermatology- Site Number : 8401076
    Fort Smith, Arkansas 72916, United States
  • Encino Research Center- Site Number : 8401042
    Encino, California 91436, United States
  • First OC Dermatology- Site Number : 8401025
    Fountain Valley, California 92708, United States
  • Center for Dermatology Clinical Research- Site Number : 8401018
    Fremont, California 94538, United States
  • Marvel Clinical Research- Site Number : 8401102
    Huntington Beach, California 92647, United States
  • Sunwise Clinical Research- Site Number : 8401022
    Lafayette, California 94549, United States
  • Torrance Clinical Research - Narbonne Avenue- Site Number : 8401027
    Lomita, California 90717, United States
  • Dermatology Research Associates - Los Angeles- Site Number : 8401092
    Los Angeles, California 90045, United States
  • LA Universal Research Center- Site Number : 8401064
    Los Angeles, California 90057, United States
  • Northridge Clinical Trials - Northridge- Site Number : 8401080
    Northridge, California 91325, United States
  • Cura Clinical Research - Oxnard- Site Number : 8401142
    Oxnard, California 93030, United States
  • Southern California Dermatology- Site Number : 8401043
    Santa Ana, California 92701, United States
  • Clinical Science Institute- Site Number : 8401028
    Santa Monica, California 90404, United States
  • UConn Health - Farmington- Site Number : 8401115
    Farmington, Connecticut 06030, United States
  • Pediatric Skin Research- Site Number : 8401198
    Coral Gables, Florida 33146, United States
  • St. Jude Clinical Research- Site Number : 8401287
    Doral, Florida 33172, United States
  • Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8401286
    Fort Myers, Florida 33919, United States
  • Direct Helpers Research Center- Site Number : 8401056
    Hialeah, Florida 33012, United States
  • Encore Medical Research - Hollywood- Site Number : 8401030
    Hollywood, Florida 33024, United States
  • Clever Medical Research- Site Number : 8401160
    Miami, Florida 33126, United States
  • Acevedo Clinical Research Associates- Site Number : 8401088
    Miami, Florida 33142, United States
  • Florida International Research Center- Site Number : 8401091
    Miami, Florida 33173, United States
  • Miami Dermatology and Laser Research - Miami - Southwest 87th Avenue- Site Number : 8401086
    Miami, Florida 33173, United States
  • Anchor Medical Research- Site Number : 8401300
    Miami, Florida 33176, United States
  • Savin Medical Group - Miami Lakes- Site Number : 8401085
    Miami Lakes, Florida 33014, United States
  • Nuline Clinical Trial Center- Site Number : 8401161
    Pompano Beach, Florida 33060, United States
  • Global Clinical Professionals (GCP)- Site Number : 8401045
    St. Petersburg, Florida 33705, United States
  • Clinical Research Trials of Florida- Site Number : 8401023
    Tampa, Florida 33607, United States
  • AllerVie Clinical Research - Columbus- Site Number : 8401104
    Columbus, Georgia 31904, United States
  • Cleaver Medical Group- Site Number : 8401138
    Dawsonville, Georgia 30534, United States
  • First Georgia Physician Group- Site Number : 8401190
    Fayetteville, Georgia 30214, United States
  • Skin Care Physicians of Georgia - Macon- Site Number : 8401034
    Macon, Georgia 31217, United States
  • Javara Research - Thomasville- Site Number : 8401189
    Thomasville, Georgia 31792, United States
  • Rophe Adult & Pediatric Medicine- Site Number : 8401289
    Union City, Georgia 30291, United States
  • NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8401038
    Skokie, Illinois 60077, United States
  • Dawes Fretzin Clinical Research- Site Number : 8401015
    Indianapolis, Indiana 46256, United States
  • Equity Medical - Bowling Green- Site Number : 8401296
    Bowling Green, Kentucky 42104, United States
  • Skin Sciences- Site Number : 8401039
    Louisville, Kentucky 40217, United States
  • MedPharmics - Covington- Site Number : 8401137
    Covington, Louisiana 70433, United States
  • BRCR Global Gretna- Site Number : 8401243
    Gretna, Louisiana 70053, United States
  • Velocity Clinical Research - Lafayette- Site Number : 8401152
    Lafayette, Louisiana 70508, United States
  • MetroBoston Clinical Partners - Brighton- Site Number : 8401128
    Brighton, Massachusetts 02135, United States
  • Henry Ford Hospital- Site Number : 8401044
    Detroit, Michigan 48202, United States
  • Revival Research Institute - Troy- Site Number : 8401012
    Troy, Michigan 48084, United States
  • Oakland Medical Center- Site Number : 8401116
    Troy, Michigan 48085, United States
  • Allergy & Immunology Associates of Ann Arbor- Site Number : 8401078
    Ypsilanti, Michigan 48197, United States
  • SKY Integrative Medical Center/SKYCRNG - Ridgeland- Site Number : 8401058
    Ridgeland, Mississippi 39157, United States
  • Skin Specialists- Site Number : 8401068
    Omaha, Nebraska 68144, United States
  • Jubilee Clinical Research- Site Number : 8401054
    Las Vegas, Nevada 89106, United States
  • Care Access - Hoboken- Site Number : 8401132
    Hoboken, New Jersey 07030, United States
  • The University of New Mexico- Site Number : 8401263
    Albuquerque, New Mexico 87106, United States
  • Equity Medical- Site Number : 8401239
    New York, New York 10023, United States
  • Icahn School of Medicine at Mount Sinai- Site Number : 8401129
    New York, New York 10029, United States
  • Sadick Research Group - New York - Park Avenue- Site Number : 8401050
    New York, New York 10075, United States
  • OptiSkin- Site Number : 8401163
    New York, New York 10128, United States
  • AXIS Clinicals - Fargo- Site Number : 8401196
    Fargo, North Dakota 58103, United States
  • Bexley Dermatology Research- Site Number : 8401051
    Bexley, Ohio 43209, United States
  • Apex Clinical Research Center- Site Number : 8401237
    Mayfield Heights, Ohio 44124, United States
  • Oregon Medical Research Center- Site Number : 8401017
    Portland, Oregon 97201, United States
  • Best Skin Research - Camp Hill- Site Number : 8401031
    Camp Hill, Pennsylvania 17011, United States
  • Paddington Testing Company- Site Number : 8401041
    Philadelphia, Pennsylvania 19103, United States
  • Clinical Research of Philadelphia- Site Number : 8401193
    Philadelphia, Pennsylvania 19114, United States
  • Dermatology Associates of Plymouth Meeting- Site Number : 8401147
    Plymouth Meeting, Pennsylvania 19462, United States
  • Columbia Dermatology & Aesthetics- Site Number : 8401166
    Columbia, South Carolina 29212, United States
  • Tribe Clinical Research - Greenville - Verdae Boulevard- Site Number : 8401225
    Greenville, South Carolina 29607, United States
  • Health Concepts- Site Number : 8401059
    Rapid City, South Dakota 57702, United States
  • Arlington Research Center- Site Number : 8401248
    Arlington, Texas 76011, United States
  • Dermatology Treatment and Research Center- Site Number : 8401164
    Dallas, Texas 75230, United States
  • Derm Texas- Site Number : 8401217
    Dallas, Texas 75235, United States
  • Prolato Clinical Research Center- Site Number : 8401209
    Houston, Texas 77054, United States
  • SMS Clinical Research- Site Number : 8401182
    Mesquite, Texas 75149, United States
  • Synapse Clinical Research - Missouri City- Site Number : 8401148
    Missouri City, Texas 77459, United States
  • Texas Dermatology and Laser Specialists - San Antonio - Oakwell Court- Site Number : 8401131
    San Antonio, Texas 78218, United States
  • Stryde Research - Epiphany Dermatology- Site Number : 8401185
    Southlake, Texas 76092, United States
  • Complete Dermatology - Sugar Land- Site Number : 8401061
    Sugar Land, Texas 77479, United States
  • Tanner Clinic - Layton Antelope A- Site Number : 8401151
    Layton, Utah 84041, United States
  • Care Access - Arlington- Site Number : 8401134
    Arlington, Virginia 22206, United States
  • Virginia Dermatology & Skin Cancer Center- Site Number : 8401047
    Norfolk, Virginia 23502, United States
  • Investigational Site Number : 0320021
    Berazategui, Buenos Aires 1886, Argentina
  • Investigational Site Number : 0320017
    Pilar, Buenos Aires 1629, Argentina
  • Investigational Site Number : 0320006
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320007
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320015
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320024
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Investigational Site Number : 0320020
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
  • Investigational Site Number : 0320022
    Buenos Aires, 1012, Argentina
  • Investigational Site Number : 0320023
    Buenos Aires, 1028, Argentina
  • Investigational Site Number : 0320011
    Buenos Aires, 1035, Argentina
  • Investigational Site Number : 0320016
    Buenos Aires, 1055, Argentina
  • Investigational Site Number : 0320008
    Buenos Aires, 1061, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1121, Argentina
  • Investigational Site Number : 0320018
    Buenos Aires, 1178, Argentina
  • Investigational Site Number : 0320010
    Buenos Aires, 1414, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0320004
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0320009
    Buenos Aires, 1425, Argentina

Showing the first 100 of 324 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Jun 2026, 25 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 25 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2024
First posted
May 9, 2024
StartActual
May 8, 2024
Primary completionActual
Jun 10, 2026
CompletionEst.
Mar 17, 2027
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06407934
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 9, 2024
Start date
May 8, 2024
Primary completion
Jun 10, 2026
Completion
Mar 17, 2027 (estimated)
Last update
Jul 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion